Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers logo overlaid on medical syringes, measuring tape, and financial charts symbolizing telehealth weight-loss market growth. Key Points Hims & Hers has shifted from offering controversial compounded GLP-1s to a formal agreement with Novo Nordisk, allowing the platform to distribute FDA-approved Ozempic and Wegovy. Following the announcement, HIMS shares surged nearly 46%, helping the stock recover from a 59% drop earlier in the year caused by previous legal friction with Novo Nordisk. Analysts ...